[Product/Solution] Rapid Coagulation and Bone Repair Dual-Mode Wound Repair Technology

1. Brief introduction

This dual-mode wound repair material, based on a water-triggered instantaneous hemostatic gel and rapid bone repair, achieves rapid hemostasis through a synergistic multi-mechanism: wound drying + adhesive closure + amplified coagulation + rapid bone repair. The innovation of this hydroxyapatite gradient tissue engineering material lies in its three-stage repair system: molecular activation, structural remodeling, and functional regeneration. It boasts a coagulation time of ≤30 seconds, adhesive strength ≥25 kPa, degradation cycle ≤7 days, and a bacterial inhibition rate ≥95%. It is suitable for irregular/deep wounds and meets ISO 9001 standards for biocompatibility. 10993 certified), non-cytotoxic, and meets portability standards for field emergency response. The 200-500μm bone material's directional pore size promotes osteoblast ingrowth, and its elastic modulus (2-5GPa) matches that of human cancellous bone (0.1-5GPa), avoiding stress shielding. It degrades by 30%-40% within 6 months, matching the rate of autologous bone regeneration (conventional sintered HA scaffold degradation is <10%/year).

2. Application field

This technology can be applied to battlefield emergency response systems and civilian trauma repair systems: osteoinductive bone repair materials combined with portable hemostatic gels or patches (such as nanocomposite gels) can rapidly control heavy bleeding. Achieve immediate repair of bone defects in emergency situations.

3. Application prospects

In 2024, the number of orthopedic surgeries related to bone defect repair in China is expected to reach 24.593 million, with a compound annual growth rate of 18.15%. The hemostatic material market is expected to reach tens of billions of dollars by 2025, with a significant increase in the share of biomaterials and nanomaterials. Convatec's fibrin glue (FDA-approved) from the United States stops bleeding in 90 seconds but requires refrigerated shipping, resulting in a high cost ($500/tube). Medtrade's zeolite hemostatic powder from the United Kingdom has strong adsorption properties but can easily cause burns and is not suitable for cavitary wounds. Zimmer's Biomet's high-end titanium alloy/ceramic materials are primarily used for load-bearing bone repair, but they lack bioactivity. Calcium phosphate materials degrade rapidly, easily leading to structural collapse. A domestic medical company's biomimetic HA material has a precise stoichiometric ratio, but traditional sintering processes destroy its nanostructure. This technology addresses the loss of bioactivity caused by high-temperature sintering (the crystallinity of HA in traditional processes is <70%, while this project achieves ≥90%). Neutral binder technology (pH 6.8-7.2) prevents cell damage from strong acid/alkaline environments, increasing cell survival to ≥95%, and presents promising market prospects.

4. Intellectual property rights

We hold four valid invention patents and two software copyrights, all held solely by the research unit.

More information about REBIO GROUP's bio-medicare service can be found here. If you are interested with such Product/Solution, please do not hesitate to contact us